Ciara C. O’Sullivan

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Rachel A. Freedman, Rebecca Gelman, Carey K. Anders et al. · Journal of Clinical Oncology · 2019 · 338 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Anne M. Noonan, Kristen Bunch, Jin‐Qiu Chen et al. · Cancer · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

Jennifer K. Litton, Meredith M. Regan, Lajos Pusztai et al. · Journal of Clinical Oncology · 2023 · 100 citations · Full text

Medicine, Oncology, Breast Oncology +16

The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer

Ciara C. O’Sullivan, Maureen Edgerly, Margarita Velarde et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 98 citations · Full text

Medicine, Oncology, Pharmacology +17

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany et al. · Annals of Oncology · 2023 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17